Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
REGULATORY
COVID-19 Vaccine Label Revised to Warn of Myocarditis Risk in Young Men
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on October 15 informing of label revisions for COVID-19 vaccines developed by Moderna and Pfizer regarding the risks of myocarditis and pericarditis in young men. The label revision follows…
To read the full story
Related Article
- 2 mRNA Jabs Ordered to Add Myocarditis to ADR List: Label Revision
December 6, 2021
- MHLW Panel OKs Use of Pfizer COVID-19 Jab for Moderna-Vaccinated Young Men
October 18, 2021
REGULATORY
- SCARDA to Beef Up Efforts to Discover Technologies Outside Infectious Diseases: AMED President
February 3, 2023
- MHLW Scratching Head over High-Price Drug Issue, Lecanemab in Mind: Bureau Chief
February 2, 2023
- Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica Now in Line for Approval
February 2, 2023
- J-TEC’s Cell Sheet for Vitiligo Up for MHLW Panel Review Feb. 13
February 1, 2023
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…